Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
复制标题
DOI：
10.1016/j.envres.2020.109858
复制
发表时间：
2020-09-01
影响因子：
8.3
通讯作者：
Poulas, Konstantinos
中科院分区：
文献类型：
--
作者：
Angelopoulou, Athina;Alexandris, Nikos;Poulas, Konstantinos
根据最近的许多出版物，COVID-19患者具有淋巴细胞减少症、较高的感染相关生物标志物和几种升高的炎性细胞因子（即肿瘤坏死因子（TNE）-α、白细胞介素IL-2 R和IL-6）。B细胞、T细胞和NK细胞的总数显著降低。RNA病毒，包括SARS-CoV-2，通过TLR 3，7和8攻击先天免疫系统以引起感染。咪喹莫特是一种激活TLR 7的免疫刺激剂，可用于增强先天性和适应性免疫。建议进行临床前和临床试验。
According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNE)-alpha, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.